ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO854

The (R)-Enantiomer of the 6-Chromanol Derivate SUL-121 Counteracts Renal Vasoconstriction by Antagonism of the Α1-Adrenoceptor

Session Information

  • Transplantation: Basic
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1801 Transplantation: Basic

Authors

  • Nakladal, Dalibor, Department of Clinical Pharmacology, University of Groningen / University Medical Center Groningen, Groningen, Netherlands
  • Buikema, Hendrik, Department of Clinical Pharmacology, University of Groningen / University Medical Center Groningen, Groningen, Netherlands
  • Reyes romero, Atilio, University of Groningen, Groningen, Netherlands
  • Krenning, Guido, University Medical Center Groningen/ University of Groningen, Groningen, Netherlands
  • Henning, Robert H., Department of Clinical Pharmacology, University of Groningen / University Medical Center Groningen, Groningen, Netherlands
  • Deelman, Leo E., Department of Clinical Pharmacology, University of Groningen / University Medical Center Groningen, Groningen, Netherlands
Background

In kidney transplantation, impaired graft perfusion associates with decreased graft survival. Disturbed adrenergic signal transduction during rewarming is an important factor limiting renal perfusion. Recently, we developed a class of 6-chromanol based SUL-compounds which maintain mitochondrial function and limit reactive oxygen species (ROS) during cooling and metabolic stress. Here, we investigate the effects of SUL-121 on vascular function of porcine kidneys.

Methods

Porcine kidneys were collected at a local slaughterhouse and immediately flushed with UW with heparin, placed on ice and transported to the laboratory. The effects of SUL-121 and its enantiomers (R)-SUL-150 and (S)-SUL-151 on renal perfusion pressure was assessed in an isolated kidney perfusion system. In addition, rings from isolated intrarenal arteries were used to measure constriction responses to various agonists after pre-incubation with SUL-compounds. Receptor binding and intracellular calcium transients were assessed in α1 adrenoceptor transgenic CHO cells. Molecular docking simulation was performed in an α1 adrenoceptor flexible homology model using Induced Fit software.

Results

Addition of SUL-121, SUL-150 but not SUL-151 caused a decrease (-11±1, -13±2 and -1±1 mmHg, respectively) in renal perfusion pressure. Pre-incubation with SUL-121 and SUL-150 competitively inhibited contraction responses to the α1 adrenoceptor agonist phenylephrine (pA2 5.37±0.03). SUL-151, other 6-chromanols and their metabolites were without effect. Contraction responses to histamine and U46619 were not influenced by SUL-150. Phenylephrine-induced calcium signalling was similarly inhibited by SUL-150 in transgenic CHO cells (pA2 5.31±0.03). SUL-150 effectively displaced radiolabelled prazosin in a competitive binding assay. Simulation of molecular docking demonstrated shared binding characteristics of SUL-150 and prazosin.

Conclusion

SUL-150, the (R)-enantiomer of SUL-121, is an antagonist of the α1 adrenoceptor with ligand-receptor interactions similar to prazosin. Considering the improvement of renal perfusion through adrenergic antagonism in addition to previously reported beneficial effect on mitochondrial function and ROS production, we propose SUL-150 as a novel and unique protectant in kidney transplantation.

Funding

  • Commercial Support